Worldview national ranking of health biotech sectors
A current Nature study specifies the most competitive health biotech sectors worldwide and puts Switzerland at the top, Sweden second and the USA third. Does the new math convince?
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1125 entries already.
Entries by Thomas Gabrielczyk
GSK splits off consumer health as Haleon – first stock listing today
/in News/by Thomas GabrielczykGlaxoSmithKline (GSK), one of the UKs large pharma player, has voted to spin-off its consumer healthcare business into a new company called Haleon. Shareholders gave the go-ahead for GSK to demerge on […]
Polpharma Biologics Announces EMA Acceptance for Proposed Biosimilar Natalizumab (Tysabri)
/in News/by Thomas GabrielczykEuropean Medicines Agency (EMA) has accepted the application for biosimilar natalizumab, a proposed biosimilar to Tysabri® (Biogen) in the indication of Multiple Sclerosis (MS).
Agomab extenses Series B with USD40m Bringing Total Amount to USD114m
/in News/by Thomas GabrielczykAgomab Therapeutics NV from Ghent, Belgium, today announced it has extended its Series B financing round with an additional close of $40.5 million (38.4 million), bringing the total Series B […]
Spatial Biology Company Navinci (Olink) closes EUR9m Series A
/in News/by Thomas GabrielczykNavinci Diagnostics AB, a Swedish life science company formerly known as Olink developing innovative tools for spatial proteomics research, announces the closing of SEK 90 million financing. The round was […]
Swedish SOBI awarded rights to market Zynlonta from ADC therapeutics
/in News/by Thomas GabrielczykIn a deal worth around USD435m Swiss ADC therapeutics grants Swedish Orphan Biovitrum (SOBI) the rights to market freshly approved Zynlonta outside the US.
ECBF joins Novo Seeds and Sofinnova Partners in EUR11.5m round in Biosyntia
/in News/by Thomas GabrielczykThe European Circular Bioeconomy Fund (ECBF) expands its industrial biotechnology portfolio by joining the financing Series B of danish Biosyntia ApS. Biosyntia is a precision fermentation company focused on bio-based […]
Lonza invests CHF500m in Large-Scale Facility in Stein (CH)
/in News/by Thomas GabrielczykLarge CDMO Lonza to build a new large-scale, commercial drug product facility including fill and finish to support customers across the entire product life cycle in Switzerland, investment of CHF500m.
Evotec, Boehringer Ingelheim, and bioMérieux launch Aurobac
/in News/by Thomas GabrielczykEvotec, pharma giant Boehringer Ingelheim, and IVD specialist bioMérieux have launched a 40m joint venture to fight Antimicrobial Resistance (AMR).
Urovant Sciences cashes in $75m in licence deal from Pierre Fabre
/in News/by Thomas GabrielczykFrench drugmaker Pierre Fabre Médicaments will pay $75m for an exclusive licence to to commercialise Urovant Sciences drug vibegron for the treatment of overactive bladder in Europe.